カテゴリ： GlobalInfoResearch, 世界, 医療/バイオ

世界の3CLプロテアーゼ阻害剤市場2022年：市場規模予測（～2028年）

■ 英語タイトル：Global 3CL Protease Inhibitor Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028

調査会社GlobalInfoResearch社が発行したリサーチレポート（データ管理コード：GIR22NO19088）■ 発行会社/調査会社：GlobalInfoResearch
■ 商品コード：GIR22NO19088
■ 発行日：2022年11月（※2025年版があります。お問い合わせください。）
■ 調査対象地域：グローバル
■ 産業分野：医薬品
■ ページ数：108
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（注文後2-3日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,480 ⇒換算￥528,960見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,220 ⇒換算￥793,440見積依頼/購入/質問フォーム
Corporate User（同一法人内共有可）USD6,960 ⇒換算￥1,057,920見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※GlobalInfoResearch社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[世界の3CLプロテアーゼ阻害剤市場2022年：市場規模予測（～2028年）]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

3CLプロテアーゼ阻害剤市場レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。
GlobalInfoResearchの最新の調査によると、世界の3CLプロテアーゼ阻害剤の市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。

3CLプロテアーゼ阻害剤市場は種類と用途によって区分されます。2017年～2028年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。

種類別セグメントは次をカバーします。
・経口、注射

用途別セグメントは次のように区分されます。
・病院、医療センター、その他

世界の3CLプロテアーゼ阻害剤市場の主要な市場プレーヤーは以下のとおりです。
・Todos Medical、Pfizer、Shionogi、Enanta Pharmaceuticals、Cocrystal Pharma、Insilico Medicine、Everest Medicines、Raynovent、Simcere、Cosunter、Ascletis Pharma、Frontier Biotechnologies

地域別セグメントは次の地域・国をカバーします。
・北米（米国、カナダ、メキシコ）
・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア）
・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア）
・南アメリカ（ブラジル、アルゼンチン、コロンビア）
・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ）

本調査レポートの内容は計15章あります。
・第1章では、3CLプロテアーゼ阻害剤製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要な3CLプロテアーゼ阻害剤メーカーの企業概要、2019年～2022年までの3CLプロテアーゼ阻害剤の価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要な3CLプロテアーゼ阻害剤メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2017年～2028年までの地域別3CLプロテアーゼ阻害剤の販売量、売上、成長性を示しています。
・第5、6章では、2017年～2028年までの3CLプロテアーゼ阻害剤の種類別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2017年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2028年までの主要地域での3CLプロテアーゼ阻害剤市場予測を収録しています。
・第12章では、主要な原材料、主要なサプライヤー、および3CLプロテアーゼ阻害剤の産業チェーンを掲載しています。
・第13、14、15章では、3CLプロテアーゼ阻害剤の販売チャネル、販売業者、顧客、調査結果と結論、付録、データソースなどについて説明します。

***** 目次(一部) *****

・市場概要
- 3CLプロテアーゼ阻害剤の概要
- 種類別分析（2017年vs2021年vs2028年）：経口、注射
- 用途別分析（2017年vs2021年vs2028年）：病院、医療センター、その他
- 世界の3CLプロテアーゼ阻害剤市場規模・予測
- 世界の3CLプロテアーゼ阻害剤生産能力分析
- 市場の成長要因・阻害要因・動向
・メーカー情報（企業概要、製品概要、販売量、価格、売上）
- Todos Medical、Pfizer、Shionogi、Enanta Pharmaceuticals、Cocrystal Pharma、Insilico Medicine、Everest Medicines、Raynovent、Simcere、Cosunter、Ascletis Pharma、Frontier Biotechnologies
・メーカー別市場シェア・市場集中度
・地域別市場分析2017年-2028年
・種類別分析2017年-2028年：経口、注射
・用途別分析2017年-2028年：病院、医療センター、その他
・3CLプロテアーゼ阻害剤の北米市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：アメリカ、カナダ、メキシコなど
・3CLプロテアーゼ阻害剤のヨーロッパ市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど
・3CLプロテアーゼ阻害剤のアジア市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど
・3CLプロテアーゼ阻害剤の南米市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：ブラジル、アルゼンチンなど
・3CLプロテアーゼ阻害剤の中東・アフリカ市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

The 3CL Protease Inhibitor market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global 3CL Protease Inhibitor market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during forecast period 2022-2028. Hospital accounting for % of the 3CL Protease Inhibitor global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Oral segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of 3CL Protease Inhibitor include Todos Medical, Pfizer, Shionogi, Enanta Pharmaceuticals, and Cocrystal Pharma, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
3CL Protease Inhibitor market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Oral
Injection
Market segment by Application can be divided into
Hospital
Medical Center
Others
The key market players for global 3CL Protease Inhibitor market are listed below:
Todos Medical
Pfizer
Shionogi
Enanta Pharmaceuticals
Cocrystal Pharma
Insilico Medicine
Everest Medicines
Raynovent
Simcere
Cosunter
Ascletis Pharma
Frontier Biotechnologies
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe 3CL Protease Inhibitor product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of 3CL Protease Inhibitor, with price, sales, revenue and global market share of 3CL Protease Inhibitor from 2019 to 2022.
Chapter 3, the 3CL Protease Inhibitor competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the 3CL Protease Inhibitor breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and 3CL Protease Inhibitor market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of 3CL Protease Inhibitor.
Chapter 13, 14, and 15, to describe 3CL Protease Inhibitor sales channel, distributors, customers, research findings and conclusion, appendix and data source.

*** レポート目次（コンテンツ）***

1 Market Overview
1.1 3CL Protease Inhibitor Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global 3CL Protease Inhibitor Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 Oral
1.2.3 Injection
1.3 Market Analysis by Application
1.3.1 Overview: Global 3CL Protease Inhibitor Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospital
1.3.3 Medical Center
1.3.4 Others
1.4 Global 3CL Protease Inhibitor Market Size & Forecast
1.4.1 Global 3CL Protease Inhibitor Sales in Value (2017 & 2021 & 2028)
1.4.2 Global 3CL Protease Inhibitor Sales in Volume (2017-2028)
1.4.3 Global 3CL Protease Inhibitor Price (2017-2028)
1.5 Global 3CL Protease Inhibitor Production Capacity Analysis
1.5.1 Global 3CL Protease Inhibitor Total Production Capacity (2017-2028)
1.5.2 Global 3CL Protease Inhibitor Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 3CL Protease Inhibitor Market Drivers
1.6.2 3CL Protease Inhibitor Market Restraints
1.6.3 3CL Protease Inhibitor Trends Analysis
2 Manufacturers Profiles
2.1 Todos Medical
2.1.1 Todos Medical Details
2.1.2 Todos Medical Major Business
2.1.3 Todos Medical 3CL Protease Inhibitor Product and Services
2.1.4 Todos Medical 3CL Protease Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 Pfizer
2.2.1 Pfizer Details
2.2.2 Pfizer Major Business
2.2.3 Pfizer 3CL Protease Inhibitor Product and Services
2.2.4 Pfizer 3CL Protease Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 Shionogi
2.3.1 Shionogi Details
2.3.2 Shionogi Major Business
2.3.3 Shionogi 3CL Protease Inhibitor Product and Services
2.3.4 Shionogi 3CL Protease Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 Enanta Pharmaceuticals
2.4.1 Enanta Pharmaceuticals Details
2.4.2 Enanta Pharmaceuticals Major Business
2.4.3 Enanta Pharmaceuticals 3CL Protease Inhibitor Product and Services
2.4.4 Enanta Pharmaceuticals 3CL Protease Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 Cocrystal Pharma
2.5.1 Cocrystal Pharma Details
2.5.2 Cocrystal Pharma Major Business
2.5.3 Cocrystal Pharma 3CL Protease Inhibitor Product and Services
2.5.4 Cocrystal Pharma 3CL Protease Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 Insilico Medicine
2.6.1 Insilico Medicine Details
2.6.2 Insilico Medicine Major Business
2.6.3 Insilico Medicine 3CL Protease Inhibitor Product and Services
2.6.4 Insilico Medicine 3CL Protease Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 Everest Medicines
2.7.1 Everest Medicines Details
2.7.2 Everest Medicines Major Business
2.7.3 Everest Medicines 3CL Protease Inhibitor Product and Services
2.7.4 Everest Medicines 3CL Protease Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8 Raynovent
2.8.1 Raynovent Details
2.8.2 Raynovent Major Business
2.8.3 Raynovent 3CL Protease Inhibitor Product and Services
2.8.4 Raynovent 3CL Protease Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9 Simcere
2.9.1 Simcere Details
2.9.2 Simcere Major Business
2.9.3 Simcere 3CL Protease Inhibitor Product and Services
2.9.4 Simcere 3CL Protease Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10 Cosunter
2.10.1 Cosunter Details
2.10.2 Cosunter Major Business
2.10.3 Cosunter 3CL Protease Inhibitor Product and Services
2.10.4 Cosunter 3CL Protease Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11 Ascletis Pharma
2.11.1 Ascletis Pharma Details
2.11.2 Ascletis Pharma Major Business
2.11.3 Ascletis Pharma 3CL Protease Inhibitor Product and Services
2.11.4 Ascletis Pharma 3CL Protease Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.12 Frontier Biotechnologies
2.12.1 Frontier Biotechnologies Details
2.12.2 Frontier Biotechnologies Major Business
2.12.3 Frontier Biotechnologies 3CL Protease Inhibitor Product and Services
2.12.4 Frontier Biotechnologies 3CL Protease Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 3CL Protease Inhibitor Breakdown Data by Manufacturer
3.1 Global 3CL Protease Inhibitor Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global 3CL Protease Inhibitor Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in 3CL Protease Inhibitor
3.4 Market Concentration Rate
3.4.1 Top 3 3CL Protease Inhibitor Manufacturer Market Share in 2021
3.4.2 Top 6 3CL Protease Inhibitor Manufacturer Market Share in 2021
3.5 Global 3CL Protease Inhibitor Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and 3CL Protease Inhibitor Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global 3CL Protease Inhibitor Market Size by Region
4.1.1 Global 3CL Protease Inhibitor Sales in Volume by Region (2017-2028)
4.1.2 Global 3CL Protease Inhibitor Revenue by Region (2017-2028)
4.2 North America 3CL Protease Inhibitor Revenue (2017-2028)
4.3 Europe 3CL Protease Inhibitor Revenue (2017-2028)
4.4 Asia-Pacific 3CL Protease Inhibitor Revenue (2017-2028)
4.5 South America 3CL Protease Inhibitor Revenue (2017-2028)
4.6 Middle East and Africa 3CL Protease Inhibitor Revenue (2017-2028)
5 Market Segment by Type
5.1 Global 3CL Protease Inhibitor Sales in Volume by Type (2017-2028)
5.2 Global 3CL Protease Inhibitor Revenue by Type (2017-2028)
5.3 Global 3CL Protease Inhibitor Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global 3CL Protease Inhibitor Sales in Volume by Application (2017-2028)
6.2 Global 3CL Protease Inhibitor Revenue by Application (2017-2028)
6.3 Global 3CL Protease Inhibitor Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America 3CL Protease Inhibitor Sales by Type (2017-2028)
7.2 North America 3CL Protease Inhibitor Sales by Application (2017-2028)
7.3 North America 3CL Protease Inhibitor Market Size by Country
7.3.1 North America 3CL Protease Inhibitor Sales in Volume by Country (2017-2028)
7.3.2 North America 3CL Protease Inhibitor Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe 3CL Protease Inhibitor Sales by Type (2017-2028)
8.2 Europe 3CL Protease Inhibitor Sales by Application (2017-2028)
8.3 Europe 3CL Protease Inhibitor Market Size by Country
8.3.1 Europe 3CL Protease Inhibitor Sales in Volume by Country (2017-2028)
8.3.2 Europe 3CL Protease Inhibitor Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific 3CL Protease Inhibitor Sales by Type (2017-2028)
9.2 Asia-Pacific 3CL Protease Inhibitor Sales by Application (2017-2028)
9.3 Asia-Pacific 3CL Protease Inhibitor Market Size by Region
9.3.1 Asia-Pacific 3CL Protease Inhibitor Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific 3CL Protease Inhibitor Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America 3CL Protease Inhibitor Sales by Type (2017-2028)
10.2 South America 3CL Protease Inhibitor Sales by Application (2017-2028)
10.3 South America 3CL Protease Inhibitor Market Size by Country
10.3.1 South America 3CL Protease Inhibitor Sales in Volume by Country (2017-2028)
10.3.2 South America 3CL Protease Inhibitor Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa 3CL Protease Inhibitor Sales by Type (2017-2028)
11.2 Middle East & Africa 3CL Protease Inhibitor Sales by Application (2017-2028)
11.3 Middle East & Africa 3CL Protease Inhibitor Market Size by Country
11.3.1 Middle East & Africa 3CL Protease Inhibitor Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa 3CL Protease Inhibitor Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of 3CL Protease Inhibitor and Key Manufacturers
12.2 Manufacturing Costs Percentage of 3CL Protease Inhibitor
12.3 3CL Protease Inhibitor Production Process
12.4 3CL Protease Inhibitor Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 3CL Protease Inhibitor Typical Distributors
13.3 3CL Protease Inhibitor Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer

List of Tables
Table 1. Global 3CL Protease Inhibitor Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global 3CL Protease Inhibitor Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. Todos Medical Basic Information, Manufacturing Base and Competitors
Table 4. Todos Medical Major Business
Table 5. Todos Medical 3CL Protease Inhibitor Product and Services
Table 6. Todos Medical 3CL Protease Inhibitor Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. Pfizer Basic Information, Manufacturing Base and Competitors
Table 8. Pfizer Major Business
Table 9. Pfizer 3CL Protease Inhibitor Product and Services
Table 10. Pfizer 3CL Protease Inhibitor Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 11. Shionogi Basic Information, Manufacturing Base and Competitors
Table 12. Shionogi Major Business
Table 13. Shionogi 3CL Protease Inhibitor Product and Services
Table 14. Shionogi 3CL Protease Inhibitor Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 15. Enanta Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 16. Enanta Pharmaceuticals Major Business
Table 17. Enanta Pharmaceuticals 3CL Protease Inhibitor Product and Services
Table 18. Enanta Pharmaceuticals 3CL Protease Inhibitor Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 19. Cocrystal Pharma Basic Information, Manufacturing Base and Competitors
Table 20. Cocrystal Pharma Major Business
Table 21. Cocrystal Pharma 3CL Protease Inhibitor Product and Services
Table 22. Cocrystal Pharma 3CL Protease Inhibitor Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 23. Insilico Medicine Basic Information, Manufacturing Base and Competitors
Table 24. Insilico Medicine Major Business
Table 25. Insilico Medicine 3CL Protease Inhibitor Product and Services
Table 26. Insilico Medicine 3CL Protease Inhibitor Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 27. Everest Medicines Basic Information, Manufacturing Base and Competitors
Table 28. Everest Medicines Major Business
Table 29. Everest Medicines 3CL Protease Inhibitor Product and Services
Table 30. Everest Medicines 3CL Protease Inhibitor Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 31. Raynovent Basic Information, Manufacturing Base and Competitors
Table 32. Raynovent Major Business
Table 33. Raynovent 3CL Protease Inhibitor Product and Services
Table 34. Raynovent 3CL Protease Inhibitor Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 35. Simcere Basic Information, Manufacturing Base and Competitors
Table 36. Simcere Major Business
Table 37. Simcere 3CL Protease Inhibitor Product and Services
Table 38. Simcere 3CL Protease Inhibitor Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 39. Cosunter Basic Information, Manufacturing Base and Competitors
Table 40. Cosunter Major Business
Table 41. Cosunter 3CL Protease Inhibitor Product and Services
Table 42. Cosunter 3CL Protease Inhibitor Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 43. Ascletis Pharma Basic Information, Manufacturing Base and Competitors
Table 44. Ascletis Pharma Major Business
Table 45. Ascletis Pharma 3CL Protease Inhibitor Product and Services
Table 46. Ascletis Pharma 3CL Protease Inhibitor Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 47. Frontier Biotechnologies Basic Information, Manufacturing Base and Competitors
Table 48. Frontier Biotechnologies Major Business
Table 49. Frontier Biotechnologies 3CL Protease Inhibitor Product and Services
Table 50. Frontier Biotechnologies 3CL Protease Inhibitor Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 51. Global 3CL Protease Inhibitor Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Units)
Table 52. Global 3CL Protease Inhibitor Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 53. Market Position of Manufacturers in 3CL Protease Inhibitor, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 54. Global 3CL Protease Inhibitor Production Capacity by Company, (K Units): 2020 VS 2021
Table 55. Head Office and 3CL Protease Inhibitor Production Site of Key Manufacturer
Table 56. 3CL Protease Inhibitor New Entrant and Capacity Expansion Plans
Table 57. 3CL Protease Inhibitor Mergers & Acquisitions in the Past Five Years
Table 58. Global 3CL Protease Inhibitor Sales by Region (2017-2022) & (K Units)
Table 59. Global 3CL Protease Inhibitor Sales by Region (2023-2028) & (K Units)
Table 60. Global 3CL Protease Inhibitor Revenue by Region (2017-2022) & (USD Million)
Table 61. Global 3CL Protease Inhibitor Revenue by Region (2023-2028) & (USD Million)
Table 62. Global 3CL Protease Inhibitor Sales by Type (2017-2022) & (K Units)
Table 63. Global 3CL Protease Inhibitor Sales by Type (2023-2028) & (K Units)
Table 64. Global 3CL Protease Inhibitor Revenue by Type (2017-2022) & (USD Million)
Table 65. Global 3CL Protease Inhibitor Revenue by Type (2023-2028) & (USD Million)
Table 66. Global 3CL Protease Inhibitor Price by Type (2017-2022) & (US$/Unit)
Table 67. Global 3CL Protease Inhibitor Price by Type (2023-2028) & (US$/Unit)
Table 68. Global 3CL Protease Inhibitor Sales by Application (2017-2022) & (K Units)
Table 69. Global 3CL Protease Inhibitor Sales by Application (2023-2028) & (K Units)
Table 70. Global 3CL Protease Inhibitor Revenue by Application (2017-2022) & (USD Million)
Table 71. Global 3CL Protease Inhibitor Revenue by Application (2023-2028) & (USD Million)
Table 72. Global 3CL Protease Inhibitor Price by Application (2017-2022) & (US$/Unit)
Table 73. Global 3CL Protease Inhibitor Price by Application (2023-2028) & (US$/Unit)
Table 74. North America 3CL Protease Inhibitor Sales by Country (2017-2022) & (K Units)
Table 75. North America 3CL Protease Inhibitor Sales by Country (2023-2028) & (K Units)
Table 76. North America 3CL Protease Inhibitor Revenue by Country (2017-2022) & (USD Million)
Table 77. North America 3CL Protease Inhibitor Revenue by Country (2023-2028) & (USD Million)
Table 78. North America 3CL Protease Inhibitor Sales by Type (2017-2022) & (K Units)
Table 79. North America 3CL Protease Inhibitor Sales by Type (2023-2028) & (K Units)
Table 80. North America 3CL Protease Inhibitor Sales by Application (2017-2022) & (K Units)
Table 81. North America 3CL Protease Inhibitor Sales by Application (2023-2028) & (K Units)
Table 82. Europe 3CL Protease Inhibitor Sales by Country (2017-2022) & (K Units)
Table 83. Europe 3CL Protease Inhibitor Sales by Country (2023-2028) & (K Units)
Table 84. Europe 3CL Protease Inhibitor Revenue by Country (2017-2022) & (USD Million)
Table 85. Europe 3CL Protease Inhibitor Revenue by Country (2023-2028) & (USD Million)
Table 86. Europe 3CL Protease Inhibitor Sales by Type (2017-2022) & (K Units)
Table 87. Europe 3CL Protease Inhibitor Sales by Type (2023-2028) & (K Units)
Table 88. Europe 3CL Protease Inhibitor Sales by Application (2017-2022) & (K Units)
Table 89. Europe 3CL Protease Inhibitor Sales by Application (2023-2028) & (K Units)
Table 90. Asia-Pacific 3CL Protease Inhibitor Sales by Region (2017-2022) & (K Units)
Table 91. Asia-Pacific 3CL Protease Inhibitor Sales by Region (2023-2028) & (K Units)
Table 92. Asia-Pacific 3CL Protease Inhibitor Revenue by Region (2017-2022) & (USD Million)
Table 93. Asia-Pacific 3CL Protease Inhibitor Revenue by Region (2023-2028) & (USD Million)
Table 94. Asia-Pacific 3CL Protease Inhibitor Sales by Type (2017-2022) & (K Units)
Table 95. Asia-Pacific 3CL Protease Inhibitor Sales by Type (2023-2028) & (K Units)
Table 96. Asia-Pacific 3CL Protease Inhibitor Sales by Application (2017-2022) & (K Units)
Table 97. Asia-Pacific 3CL Protease Inhibitor Sales by Application (2023-2028) & (K Units)
Table 98. South America 3CL Protease Inhibitor Sales by Country (2017-2022) & (K Units)
Table 99. South America 3CL Protease Inhibitor Sales by Country (2023-2028) & (K Units)
Table 100. South America 3CL Protease Inhibitor Revenue by Country (2017-2022) & (USD Million)
Table 101. South America 3CL Protease Inhibitor Revenue by Country (2023-2028) & (USD Million)
Table 102. South America 3CL Protease Inhibitor Sales by Type (2017-2022) & (K Units)
Table 103. South America 3CL Protease Inhibitor Sales by Type (2023-2028) & (K Units)
Table 104. South America 3CL Protease Inhibitor Sales by Application (2017-2022) & (K Units)
Table 105. South America 3CL Protease Inhibitor Sales by Application (2023-2028) & (K Units)
Table 106. Middle East & Africa 3CL Protease Inhibitor Sales by Region (2017-2022) & (K Units)
Table 107. Middle East & Africa 3CL Protease Inhibitor Sales by Region (2023-2028) & (K Units)
Table 108. Middle East & Africa 3CL Protease Inhibitor Revenue by Region (2017-2022) & (USD Million)
Table 109. Middle East & Africa 3CL Protease Inhibitor Revenue by Region (2023-2028) & (USD Million)
Table 110. Middle East & Africa 3CL Protease Inhibitor Sales by Type (2017-2022) & (K Units)
Table 111. Middle East & Africa 3CL Protease Inhibitor Sales by Type (2023-2028) & (K Units)
Table 112. Middle East & Africa 3CL Protease Inhibitor Sales by Application (2017-2022) & (K Units)
Table 113. Middle East & Africa 3CL Protease Inhibitor Sales by Application (2023-2028) & (K Units)
Table 114. 3CL Protease Inhibitor Raw Material
Table 115. Key Manufacturers of 3CL Protease Inhibitor Raw Materials
Table 116. Direct Channel Pros & Cons
Table 117. Indirect Channel Pros & Cons
Table 118. 3CL Protease Inhibitor Typical Distributors
Table 119. 3CL Protease Inhibitor Typical Customers
List of Figures
Figure 1. 3CL Protease Inhibitor Picture
Figure 2. Global 3CL Protease Inhibitor Revenue Market Share by Type in 2021
Figure 3. Oral
Figure 4. Injection
Figure 5. Global 3CL Protease Inhibitor Revenue Market Share by Application in 2021
Figure 6. Hospital
Figure 7. Medical Center
Figure 8. Others
Figure 9. Global 3CL Protease Inhibitor Revenue, (USD Million) & (K Units): 2017 & 2021 & 2028
Figure 10. Global 3CL Protease Inhibitor Revenue and Forecast (2017-2028) & (USD Million)
Figure 11. Global 3CL Protease Inhibitor Sales (2017-2028) & (K Units)
Figure 12. Global 3CL Protease Inhibitor Price (2017-2028) & (US$/Unit)
Figure 13. Global 3CL Protease Inhibitor Production Capacity (2017-2028) & (K Units)
Figure 14. Global 3CL Protease Inhibitor Production Capacity by Geographic Region: 2022 VS 2028
Figure 15. 3CL Protease Inhibitor Market Drivers
Figure 16. 3CL Protease Inhibitor Market Restraints
Figure 17. 3CL Protease Inhibitor Market Trends
Figure 18. Global 3CL Protease Inhibitor Sales Market Share by Manufacturer in 2021
Figure 19. Global 3CL Protease Inhibitor Revenue Market Share by Manufacturer in 2021
Figure 20. 3CL Protease Inhibitor Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 21. Top 3 3CL Protease Inhibitor Manufacturer (Revenue) Market Share in 2021
Figure 22. Top 6 3CL Protease Inhibitor Manufacturer (Revenue) Market Share in 2021
Figure 23. Global 3CL Protease Inhibitor Sales Market Share by Region (2017-2028)
Figure 24. Global 3CL Protease Inhibitor Revenue Market Share by Region (2017-2028)
Figure 25. North America 3CL Protease Inhibitor Revenue (2017-2028) & (USD Million)
Figure 26. Europe 3CL Protease Inhibitor Revenue (2017-2028) & (USD Million)
Figure 27. Asia-Pacific 3CL Protease Inhibitor Revenue (2017-2028) & (USD Million)
Figure 28. South America 3CL Protease Inhibitor Revenue (2017-2028) & (USD Million)
Figure 29. Middle East & Africa 3CL Protease Inhibitor Revenue (2017-2028) & (USD Million)
Figure 30. Global 3CL Protease Inhibitor Sales Market Share by Type (2017-2028)
Figure 31. Global 3CL Protease Inhibitor Revenue Market Share by Type (2017-2028)
Figure 32. Global 3CL Protease Inhibitor Price by Type (2017-2028) & (US$/Unit)
Figure 33. Global 3CL Protease Inhibitor Sales Market Share by Application (2017-2028)
Figure 34. Global 3CL Protease Inhibitor Revenue Market Share by Application (2017-2028)
Figure 35. Global 3CL Protease Inhibitor Price by Application (2017-2028) & (US$/Unit)
Figure 36. North America 3CL Protease Inhibitor Sales Market Share by Type (2017-2028)
Figure 37. North America 3CL Protease Inhibitor Sales Market Share by Application (2017-2028)
Figure 38. North America 3CL Protease Inhibitor Sales Market Share by Country (2017-2028)
Figure 39. North America 3CL Protease Inhibitor Revenue Market Share by Country (2017-2028)
Figure 40. United States 3CL Protease Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 41. Canada 3CL Protease Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 42. Mexico 3CL Protease Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 43. Europe 3CL Protease Inhibitor Sales Market Share by Type (2017-2028)
Figure 44. Europe 3CL Protease Inhibitor Sales Market Share by Application (2017-2028)
Figure 45. Europe 3CL Protease Inhibitor Sales Market Share by Country (2017-2028)
Figure 46. Europe 3CL Protease Inhibitor Revenue Market Share by Country (2017-2028)
Figure 47. Germany 3CL Protease Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 48. France 3CL Protease Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 49. United Kingdom 3CL Protease Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 50. Russia 3CL Protease Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. Italy 3CL Protease Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. Asia-Pacific 3CL Protease Inhibitor Sales Market Share by Region (2017-2028)
Figure 53. Asia-Pacific 3CL Protease Inhibitor Sales Market Share by Application (2017-2028)
Figure 54. Asia-Pacific 3CL Protease Inhibitor Sales Market Share by Region (2017-2028)
Figure 55. Asia-Pacific 3CL Protease Inhibitor Revenue Market Share by Region (2017-2028)
Figure 56. China 3CL Protease Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 57. Japan 3CL Protease Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 58. Korea 3CL Protease Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. India 3CL Protease Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. Southeast Asia 3CL Protease Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. Australia 3CL Protease Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. South America 3CL Protease Inhibitor Sales Market Share by Type (2017-2028)
Figure 63. South America 3CL Protease Inhibitor Sales Market Share by Application (2017-2028)
Figure 64. South America 3CL Protease Inhibitor Sales Market Share by Country (2017-2028)
Figure 65. South America 3CL Protease Inhibitor Revenue Market Share by Country (2017-2028)
Figure 66. Brazil 3CL Protease Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 67. Argentina 3CL Protease Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 68. Middle East & Africa 3CL Protease Inhibitor Sales Market Share by Type (2017-2028)
Figure 69. Middle East & Africa 3CL Protease Inhibitor Sales Market Share by Application (2017-2028)
Figure 70. Middle East & Africa 3CL Protease Inhibitor Sales Market Share by Region (2017-2028)
Figure 71. Middle East & Africa 3CL Protease Inhibitor Revenue Market Share by Region (2017-2028)
Figure 72. Turkey 3CL Protease Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 73. Egypt 3CL Protease Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. Saudi Arabia 3CL Protease Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. South Africa 3CL Protease Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. Manufacturing Cost Structure Analysis of 3CL Protease Inhibitor in 2021
Figure 77. Manufacturing Process Analysis of 3CL Protease Inhibitor
Figure 78. 3CL Protease Inhibitor Industrial Chain
Figure 79. Sales Channel: Direct Channel vs Indirect Channel
Figure 80. Methodology
Figure 81. Research Process and Data Source


*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 世界の抗レトロウイルスプロテアーゼ阻害剤市場2022年：市場規模予測（～2028年）
  • 世界の3CLプロテアーゼアッセイキット市場2022年：市場規模予測（～2028年）
  • 世界のセリンプロテアーゼ市場2022年：市場規模予測（～2028年）
  • 世界のCDK4及び6阻害医薬品市場2022年：市場規模予測（～2028年）
  • 世界のプラスミノーゲンアクチベーターインヒビター1市場2022年：市場規模予測（～2028年）
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(GIR22NO19088 )"世界の3CLプロテアーゼ阻害剤市場2022年：市場規模予測（～2028年）" (英文：Global 3CL Protease Inhibitor Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028)はGlobalInfoResearch社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。